Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$11,522 Mln
P/E Ratio
--
P/B Ratio
3.25
Industry P/E
37.44
Debt to Equity
0
ROE
-0.11 %
ROCE
-11.59 %
Div. Yield
0 %
Book Value
--
EPS
-2.27
CFO
$3,000.40 Mln
EBITDA
$3,396.80 Mln
Net Profit
$1,695.70 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Catalent (CTLT)
| 41.33 | 7.45 | 5.55 | 53.09 | -20.62 | 3.64 | 8.31 |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Catalent (CTLT)
| -0.18 | -64.84 | 23.02 | 84.85 | 80.56 | -23.99 | 52.37 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer... Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey. Read more
President, CEO & Director
Mr. Alessandro Maselli
Executive Chairman of the Board
Mr. John J. Greisch M.B.A.
Headquarters
Somerset, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Catalent Inc (CTLT) stood at $ 12,215 Mln as on 30-Sep-24
The share price of Catalent Inc (CTLT) is $63.50 (NYSE) as of 17-Dec-2024 19:26 EDT. Catalent Inc (CTLT) has given a return of -20.62% in the last 3 years.
Catalent Inc (CTLT) has a market capitalisation of $ 11,522 Mln as on 17-Dec-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Catalent Inc (CTLT) is 3.25 times as on 17-Dec-2024, a 36% discount to its peers’ median range of 5.04 times.
Since, TTM earnings of Catalent Inc (CTLT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Catalent Inc (CTLT) and enter the required number of quantities and click on buy to purchase the shares of Catalent Inc (CTLT).
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
The CEO & director of Mr. Alessandro Maselli. is Catalent Inc (CTLT), and CFO & Sr. VP is Mr. John J. Greisch M.B.A..
There is no promoter pledging in Catalent Inc (CTLT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Catalent Inc. (CTLT) | Ratios |
|---|---|
|
Return on equity(%)
|
-11.55
|
|
Operating margin(%)
|
-0.77
|
|
Net Margin(%)
|
-9.34
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Catalent Inc (CTLT) was $0 Mln.
$0.02
(
